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Abstract
Although the aggregation process of amyloidogenic proteins has been widely studied
in vitro and many physiological factors have been identified, the molecular mecha‐
nisms  underlying  the  formation  of  aggregates  in  vivo  and  under  pathological
conditions are still poorly understood. Post‐translational modifications are known to
affect protein structure and function. Some of these modifications might affect proteins
in detrimental ways and lead to their misfolding and accumulation. Reducing sugars
play  an  important  role  in  modifying  proteins,  forming  advanced  glycation  end‐
products (AGEs) in a nonenzymatic process, called glycation. Recently, much attention
has been devoted to the role played by glycation in stimulating amyloid aggregation
and cellular toxicity. Proteins in amyloid deposits are often found glycated, suggest‐
ing a direct correlation between protein glycation and amyloidosis.
AGE products increase in aging and are considered a marker for several diseases such
as Alzheimer disease and diabetes. In addition to directly affecting the protein structure
and function, AGEs also induce cellular toxicity.
This chapter focuses on the molecular effects induced by glycation in the amyloid
aggregation of several protein models. In particular, both the structural effects induced
by glycation and their consequence on cellular toxicity will be extensively described.
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1. Introduction
Reducing sugars play an important role in modifying proteins, forming advanced glycation
end‐products (AGEs) in a nonenzymatic process, called glycation. This process is different
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from glycosylation; indeed, these two post‐translational modifications affect the structure of
the target protein in a different way. Glycosylation is a selective protein modification, driven
by specific enzymes, that is generally associated with a gain of function (or stabilization) of
the target protein. Nonenzymatic glycation is a nonselective modification, and it is generally
associated with a loss of function of the target protein due to modifications of its native
structure. While glycosylation is a well‐controlled cellular mechanism, nonenzymatic
glycation depends on the exposure of free amino groups in the polypeptide chain, concentra‐
tion of the sugar, and oxidative conditions. Glycation is a pathological process that is highly
relevant in diabetes patients, as it plays a crucial role not only in diabetic complications but
also in the normal aging process. Increasing evidence suggests a link between diabetes and
neurodegenerative processes such as Alzheimer and Parkinson diseases [1]. In this respect,
much attention has been recently devoted to the role played by nonenzymatic glycation of
proteins in stimulating amyloid aggregation and toxicity. The observation that proteins in
amyloid deposits, such as β‐amyloid, tau, prions, transthyretin, and β2‐microglobulin, are often
found glycated in patients suggests a direct correlation between protein glycation and amyloid
formation [2–8]. This is thought to be associated with the formation of cross‐links that stabilize
protein aggregates. Indeed, AGEs formation can not only interfere with the regular function‐
ing of the proteins to which they are attached but also induce the formation of covalent cross‐
links with close proteins. In addition, glycation can affect the protein degradation process [9],
and, being an abnormal modification, it has been found to induce some proteins to misfold
and, thus, promote protein aggregation [10–12].
Moreover, the AGE‐modified proteins are tightly involved in physiopathological cellular
mechanisms. Once formed, AGEs interact with specific cellular receptors leading to the
activation of different signaling pathways. The most studied AGE‐receptor, known as RAGE,
is a multiligand receptor belonging to the immunoglobulin superfamily [13, 14]. The activa‐
tion of RAGE regulates key cellular processes such as inflammation, apoptosis, proliferation,
autophagy, and recently it has been associated with the pathogenesis of amyloidosis [15, 16].
In neurons, glia, and endothelial cells, RAGE is also the binding site for Aβ peptide on the cell
surface and mediates Alzheimer's disease pathology [15, 17, 18].
2. Protein glycation
The nonenzymatic glycation of protein amino groups by reducing sugars (also called Mail‐
lard reaction) is a chemical reaction common to all cell types: glycated products slowly ac‐
cumulate in vivo, leading to several different protein dysfunctions caused by alterations of
their integrity [19, 20]. The process begins with a nucleophilic addition reaction between a
free amino group of a protein and a carbonyl group of a reducing sugar, forming a reversi‐
ble intermediate product (Schiff's base). Side‐chains of arginine and lysine residues and the
N‐terminal amino group of proteins are the main targets of protein glycation. The process
depends on several conditions, such as the concentration and reactivity of the glycation
agent, the presence of catalytic factors (metals, buffer ions, and oxygen), the physiological
pH, temperature, and the half‐life of each protein. All reducing sugars can participate in
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glycation reactions and, among them, D‐ribose is the most active form, and its intracellular
level can be quite high. D‐glucose is the less reactive form and its intracellular concentration
is negligible, while dicarbonyl compounds, such as methylglyoxal and glyoxal, are far more
reactive. These compounds are intermediates of glycation reaction, but can also be generat‐
ed by various oxidative processes and be formed through other metabolic pathways such as
glycolysis and catabolism of threonine and ketone bodies. The levels of D‐ribose in the
blood are estimated around 20 mg/L in healthy individuals, while that of D‐glucose are
around 6–10 g/L. Once formed, the Schiff's base can convert into a stable ketoamine by
Amadori rearrangement (Figure 1). This reaction is reversible, depending on the concentra‐
tion of the reactants. The late stage of the process is an irreversible cascade of reactions in‐
volving enolization, dehydration, condensation, oxidation, fragmentation, and other
rearrangements, leading to the formation of AGEs [21]. Glucose, Schiff's base, and Amadori
product, can also exhibit auto‐oxidation reactions that are responsible for free radicals and
highly reactive carbonyl compound production. These compounds can react with other ami‐
no acid side‐chains and further contribute to post‐translational modifications. Unlike organ‐
ic syntheses, AGEs formation does not produce well‐defined products but a large number of
structures. The pathways leading to several AGEs are extensively outlined in [22]. Glycation
reaction produces very reactive intermediates that can promote the formation of intramolec‐
ular and intermolecular cross‐links within AGE‐modified protein monomers. However, the
reaction can also evolve into AGE protein adducts unable to form covalent cross‐links
(Figure 1).
Figure 1. Simplified reaction scheme of some chemical processes involved in AGE formation. The reaction between
a free amino group of a protein and the carbonyl group of a reducing sugar leads to the production of the Schiff’s base
that can turn into a stable ketoamine by Amadori rearrangement. Glycation reaction can evolve to AGE derivatives,
forming, that is, di‐aminoethyl bridge, or not forming, that is, carboxymethyl‐lysine, intramolecular and intermolecu‐
lar protein cross‐links. Adapted from Glomb and Monnier [23].
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3. Differential effects of glycation on protein aggregation and cytotoxicity
Several proteins related and not related to misfolding diseases have been so far examined to
investigate the effect of glycation on their propensity to aggregate and form amyloid structure.
3.1. Proteins related to misfolding diseases
3.1.1. Aβ‐peptide
Aβ‐peptide is crucially involved in Alzheimer's disease as the main component of the amyloid
plaques found in the brains of Alzheimer patients. This peptide results from the amyloid
precursor protein (APP), which is cleaved by beta‐secretase and gamma‐secretase. Although
carbohydrates are directly involved in the formation of neurofibrillary tangles and senile
plaques in the brains of the patients with Alzheimer disease (AD) [24–26], their influence on
the mechanism of Aβ peptide aggregation and induced cell toxicity is still controversial. Vitek
et al. [10] reported, for the first time, that plaque fractions of AD brains contained about
threefold more AGE adducts than preparations from healthy, age‐matched controls. This
observation was further corroborated by immunohistochemical studies on postmortem tissues
that identified AGEs as major components of amyloid plaques [27]. Studies in vitro have shown
that AGE‐modified Aβ peptide‐nucleation seeds induce fast aggregation of the soluble Aβ
peptide compared to nonmodified seed material [10]. Aggregation of the Aβ peptide follows
a nucleation‐dependent polymerization process, consisting of two steps, an initial slow
nucleus formation, followed by a rapid growth phase. The formation of a nucleus is a reversible
process dependent on the concentration of the peptide monomer; thus, it is likely that the
initiation of the process at a subthreshold concentration may be started by irreversible covalent
cross‐linking of the glycated monomers [10]. The AGEs species that enhance nucleation were
suggested to be the relatively early glycation products as evidenced by the time course over
which glucose accelerated the formation of Aβ peptide aggregates. Successively, it has been
reported that glycation by fructose also promotes amyloid aggregation in vitro of Aβ pep‐
tide. During the aggregation process, both nucleus formation and aggregates’ growth were
accelerated by AGE‐mediated cross‐linking [28, 29]. Specifically, an increased content of
oligomeric forms at the expense of fibrillar species was detected when Aβ peptide was
incubated in the presence of glucose or fructose [29]. These species resulted to improve cell
viability probably due to the stabilization of the oligomeric forms. Indeed, the mechanism by
which Aβ induces toxicity is intimately associated to the conformational state of the peptide,
the fibrillar forms rather than the soluble oligomers result more toxic to cells [30]. However,
increasing evidence has recently shown that soluble oligomers are also cytotoxic, both in vitro
and in vivo [31, 32]. The idea that all amyloid oligomers are intrinsically toxic has recently been
questioned by a number of evidence showing that, depending on the growth conditions, the
same protein/peptide can generate structurally different oligomers endowed with different
stability, hydrophobic exposure, compactness, and cytotoxicity [33]. Aβ oligomers display a
high degree of polymorphism with different structural, biophysical, and cytotoxic proper‐
ties. In particular, Aβ oligomers have been classified as A+ and A-, with A+ more toxic than
A- oligomers, possibly as a consequence of the increased exposure of hydrophobic residues
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that would favor their interaction with the plasma membrane [34, 35]. In this respect, glyca‐
tion could affect the structural and physicochemical features of amyloid oligomers as well as
their interaction to the cell membrane and, consequentially, induce different cytotoxicities.
Also, glycation by methylglyoxal promotes the formation of β‐sheets, oligomers, and protofi‐
brils in Aβ peptide as well as the increase in size of the oligomers, suggesting an enhance‐
ment of intermolecular and intramolecular interactions which stabilizes the aggregate
species [36].
Aβ peptide has been identified as a ligand of RAGE, and the Aβ–RAGE interaction triggers
the activation of different signaling pathways responsible for the neuronal cell death [37].
RAGE is overexpressed in the AD brains, and its upregulation has been shown to mediate Aβ‐
induced oxidative stress, activation of transcription factor Nf-κB, and apoptosis [38, 39].
Recently, Li et al. [40] have reported that fully glycated Aβ peptide (long incubation with
methylglyoxal) exacerbates the neuronal toxicity by the upregulation of RAGE and subse‐
quent activation of death‐signaling pathways. These apparently contrasting effects of the
cytotoxic properties of the glycated Aβ could be explained, assuming that glycation induces
two different mechanisms in time: an immediate cytoprotective effect, likely associated with
the structural properties of the oligomers, and a toxic effect at longer times associated to AGE
formation.
3.1.2. β2‐Microglobulin
β2 microglobulin (β2M) is a major constituent of amyloid fibrils deposited in patients with
hemodialysis‐associated amyloidosis. This type of amyloidosis is a common and serious
complication in patients on long‐term hemodialysis.
Glycation seems to promote amyloid aggregation in β2M. In particular, D‐ribose has been
shown to rapidly induce human β2M to generate AGEs and form aggregates in a time‐
dependent manner [41]. The process takes few days in vitro and proceeds through the
formation of covalent cross‐links that are likely to favor protein aggregation. Ribosylated β2M
was highly oligomerized compared to unglycated protein, and had a granular morphology
[41]. Furthermore, once ribosylated β2M aggregates have been formed, they are difficult to be
degraded by proteases and can persist in human tissues for a long period. These oligomeric
aggregates show significant cytotoxicity to human neuroblastoma and fibroblast cells. Indeed,
the exposure of cells to ribosylated β2M aggregates resulted in a significant increase of
intracellular reactive oxygen species (ROS), and thereby induced apoptosis [41]. Inhibition of
fibril extension in vitro was reported for β2M also upon glycation with D‐glucose [42]. As
glycated β2M is found as a major component of the amyloid deposits in hemodialysis‐
associated amyloidosis [2], these findings suggest that glycation could promote the forma‐
tion of stable β2‐microglobulin aggregates in vivo that contribute to the cell dysfunction and
death, thus playing an important role in the pathogenesis of β2M‐associated diseases.




Insulin is a small protein hormone that is crucial for the control of glucose metabolism.
Monomeric insulin undergoes amyloid aggregation in vivo, and insulin amyloid‐like fibrils
are the hallmark of a clinical condition observed in insulin‐dependent diabetic patients, called
insulin injection amyloidosis.
Glycation of insulin has been reported to differentially affect protein structure, stability, and
aggregation, depending on the glycating agent and/or environmental conditions. This protein
is intimately associated with glycemia and is vulnerable to glycation by glucose and other
highly reactive carbonyls, especially in diabetic conditions [43]. Glycated insulin is unable to
regulate glucose homeostasis in vivo and to stimulate glucose transport and adipose tissue
lipogenesis [44].
In vitro experiments have shown that insulin can be glycated by glucose to be able to react
with Lys29 in the C‐terminal region of chain B and with N‐terminus of chains A and B [45, 46].
Glucose induces the formation of glycated insulin adducts having different structural features,
depending on the experimental conditions used. In particular, glycation in reducing condi‐
tions is able to induce insulin oligomerization, thus accelerating amyloid formation. On the
contrary, glycation in nonreducing conditions strongly inhibit amyloid formation in a way
proportional to the glycation extent [47]. Probably, under the latter conditions, insulin adducts
possess a higher internal dynamics that prevent formation of the rigid cross‐β core structure,
thus reducing the ability to form fibrils. Human insulin can also be glycated by methylglyox‐
al able to react with a single site, that is, Arg22 of the B‐chain. This modification promotes the
formation of native‐like aggregates and reduces the ability of human insulin to form fibrils by
impairing the formation of the seeding nuclei. These aggregates are small, soluble, nonfibril‐
lar, and retain a native‐like structure. The lag‐phase of the nucleation‐dependent polymeriza‐
tion process increased as a function of methylglyoxal concentration [48]. Also, using ribose as
the glycating agent, the insulin's native conformation is preserved and does not evolve in
amyloid aggregates, because ribosylation impairs the α‐helix to β‐sheet transition, maintain‐
ing the protein in a soluble monomeric state [49]. Again, the effects may be ascribed to a higher
dynamics in glycated insulin leading to impairment in the formation of the rigid cross‐β
structure. However, ribose‐glycated insulin strongly affects the cell viability, triggering a death
pathway involving the activation of apoptotic signaling, intracellular reactive oxygen
species (ROS) production, and activation of the transcription factor Nf‐κB [49].
3.1.4. α‐Synuclein
α‐Synuclein is a natively unfolded protein which is found in the typical amyloid fibrillar form
in the intraneuronal Lewy bodies (LBs) in Parkinson's disease (PD). Several factors such as
metals, oxidative stress, failure of proper protein degradation, and mutations are associated
to the altered protein conformation and function [50, 51]. Post‐translational modifications like
phosphorylation and glycation are known to affect the α‐synuclein aggregation process [52].
Glycation was first reported to be present in the substantia nigra and locus coeruleus of
peripheral LBs [53]. Increased accumulation of AGEs was detected in neuronal LBs and glial
cells in the frontal cortex of early‐stage PD brains, suggesting a role for AGEs in the disease
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[54]. Moreover, AGEs and α‐synuclein were found similarly distributed and colocalized in
early LBs in the brains of PD patients [6, 55]. Intracellular accumulation of AGEs precedes α‐
synuclein‐positive inclusion body formation, and extracellular AGEs accelerate the process of
intracellular α‐synuclein‐positive inclusion body formation [56].
In vitro studies showed that AGEs promote cross‐linking of α‐synuclein. The protein con‐
tains 15 lysine residues making it a target for glycation at multiple sites. Glycation with both
methylglyoxal and glyoxal induces oligomerization of α‐synuclein and inhibits the forma‐
tion of amyloid fibrils [57, 58]. Under aggregation conditions, glycated α‐synuclein promot‐
ed the β‐sheet conversion and the formation of spherical aggregates which were similar to
oligomeric intermediates in their size and morphology, but no further elongation to fibrils was
observed. Moreover, protein fibrillization was significantly suppressed by the seeding of
modified α‐synuclein species [57]. However, AGEs formation did not alter the secondary
structure: the glycated α‐synuclein showed similar random coil conformation as the native
protein [57, 58]. Similar results were obtained with D‐ribose: ribosylation of α‐synuclein
promotes the formation of molten globule‐like aggregates and not fibrils. Moreover, these
aggregates induce oxidative stress in cell models and result in high cytotoxicity. Changes in
secondary structure upon ribosylation were not detected in α‐synuclein. However, conforma‐
tional changes in the tertiary structure occurred as suggested by change in intrinsic fluores‐
cence and exposure of hydrophobic patches [59]. The glycation‐induced folding alterations
might affect the aggregation kinetics of α‐synuclein inducing oligomerization and stabilize
oligomeric aggregates.
Choi and Lim [60] reported, in a mouse model of parkinsonism, that α‐synuclein is modified
by AGEs in vivo. The authors showed that an oligomeric form of α‐synuclein is linked to Nε‐
(carboxymethyl)lysine (CML) and Nε‐(carboxyethyl)lysine (CEL) suggesting that the AGEs
modification is involved in the aggregation of the α‐synuclein in vivo.
These results indicate that glycation of α‐synuclein results in the formation of oligomeric or
globular structures that are the more toxic aggregate forms. Thus, it is likely that, in a glycation‐
prone environment, more cytotoxic α‐synuclein aggregates or oligomers are formed contri‐
buting to the pathogenesis of PD.
3.1.5. Lysozime
Hen egg white lysozyme (HEWL) has also been used to study the impact of glycation on
protein structure and aggregation. HEWL is a structural homolog of human lysozyme,
responsible for systemic amyloidosis disease and, for this reason, it is considered a very good
model for amyloid aggregation studies. HEWL undergoes glycation in vitro, and potential
glycation sites are considered to be the N‐terminal α‐amino group, ε‐amino group of lysine
residues, and guanidino group of arginine residues [61]. Glycation of HEWL has been tested
over a prolonged period in the presence of D‐glucose, D‐fructose, and D‐ribose [62, 63]. Among
the tested sugars, D‐ribose resulted to be the most effective one, and glycation has been found
to promote formation of cross‐linked oligomers but no fibrillar species in HEWL. More
recently, ribosylation of HEWL in the early phase of the process has been studied by comple‐
mentary high‐resolution techniques [64]. These studies indicate that ribosylation modifies the
Role of Glycation in Amyloid: Effect on the Aggregation Process and Cytotoxicity
http://dx.doi.org/10.5772/62995
173
protein surface in HEWL without altering the overall structure but affecting its hydrophobic
surface. Such modifications lead to the formation of native‐like spherical oligomers, able to
affect cell viability, which further evolve into insoluble native‐like protofibrils [64].
3.2. Proteins not related to misfolding diseases
3.2.1. Albumin
Human serum albumin (HSA) is the most abundant protein in human plasma or serum
(around 60% of total proteins). Serum albumin is known to be capable of self‐assembling in
amyloidogenic aggregates under particular experimental conditions (pH, temperature,
concentration, and isoelectric point) and is a widely used model for the study of amyloid
aggregation. Both HSA and bovine serum albumin (BSA) have been shown to be efficiently
glycated in vitro by different glycating agents. Glycation and AGE modifications of serum
albumin induce structural changes that depend on the chemical reactivity of the modifying
reagent and the concentration used for in vitro glycation. However, glycation has been shown
to promote strong conformational changes affecting both secondary and tertiary structures.
Such modifications in tertiary structure have been revealed by complementary spectroscopi‐
cal techniques: circular dichroism (CD), Fourier transform infrared (FTIR), nuclear magnetic
resonance (NMR), and fluorescence spectroscopy [65–69]. In particular, the microenviron‐
ment of Trp214 seems to be strongly affected by glycation as indicated by fluorescence and
NMR spectroscopy [66, 69]. Such conformational changes in the tertiary structure could be a
consequence of molecular rearrangements after the formation of AGE products. Indeed, some
of these AGEs forming covalent cross‐links within adjacent protein strands require conforma‐
tional changes which produce more apolar and tight molecules with respect to the native
protein. Besides, the accessibility of the hydrophobic regions in the protein has been shown to
increase with glycation [67, 68]. Modification at the secondary structure level can be detect‐
ed only at longer times of incubation with glycating agents. This could be due to the fact that
glycation is likely to induce loss of tertiary structure before that of secondary structure, as
suggested by comparing intrinsic fluorescence and far‐UV CD results in glycated albumin [65,
66, 70].
Glycation‐induced protein misfolding promotes the formation of amyloid‐like aggregates in
serum albumin [12, 71, 72]. These amyloid‐like deposits appear as densely staining granules
under atomic force microscopy and are able to bind the amyloid‐specific dye thioflavin T. Also,
they were shown to induce high cytotoxicity that triggers cell death by activation of cellular
signaling cascades. In fact, independent experiments have shown that aggregates of glycated
BSA are able to induce ROS‐mediated oxidative stress and apoptosis in both neurotypic SH‐
SY5Y and MCF‐7 cells. These results indicate that glycation of serum albumin results in the
formation of oligomeric or globular structures that are the more toxic aggregate forms [68, 72].
These observations could have important implications, as serum albumin, being a circulat‐
ing protein, is likely undergoing glycative alteration in the case of diabetes pathology and
hyperglycemia. For instance, antioxidant activities of serum albumin were impaired in patients
with diabetes.
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3.2.2. Apomyoglobin
Apomyoglobin (i.e., heme‐free myoglobin) is a small, soluble α‐helical protein able to form
amyloid fibrils under particular experimental conditions. In addition, an apomyoglobin
mutant, that is, W7FW14F, is able to form amyloid fibrils in physiological conditions of pH
and temperature, and for this reason this protein is a good model for the study of amyloido‐
sis [73–78].
Wild‐type apomyoglobin is rapidly glycated in vitro by different glycating agents, and
glycation has been shown to induce strong conformational changes, affecting both secon‐
dary and tertiary structures. In particular, glycation induces partial loss of the helical con‐
tent in apomyoglobin without promoting an α to β transition, typical of the amyloid aggregates.
Glycation induces strong modifications in the tridimensional organization, as suggested by
the loss of ability of the glycated protein to bind the prosthetic group [79]. Such modifica‐
tions eventually lead to the formation of oligomeric species, stabilized by intermolecular cross‐
links, able to affect cell viability as observed for amyloid prefibrillar oligomeric aggregates,
specifically, cell exposure to fully glycated wild‐type apomyoglobin‐induced ROS‐mediated
apoptosis [79].
At the same time, glycation has been shown to affect the aggregation kinetics in the W7FW14F
apomyoglobin mutant, able to form amyloid fibrils in physiological conditions [73–78]. In
particular, glycation accelerates the formation of harmless amyloid fibrils in the apomyoglo‐
bin this amyloidogenic mutant [76]. A plausible explanation for such faster kinetics could be
related to a higher tendency of the mutant to form intermolecular links upon glycation able to
reduce the flexibility of aggregation‐prone regions and thus favor the subsequent step of fibril
elongation.
Although apomyoglobin is not related to any amyloidogenic diseases, it represents a suita‐
ble model for studying the role of glycation in amyloid aggregation. Indeed, due to the different
aggregation propensities of the native protein and the W7FW14F mutant in physiological
conditions, this protein model allows to dissect the effect of glycation in promoting amyloid
aggregation and contributes to the aggregation kinetics. The above results indicate that
glycation can be considered not only a triggering factor in amyloidosis but also a player in
later stages of the aggregation process.
4. Molecular effects of glycation on amyloid aggregation process
The overall evidences on several model proteins indicate that AGE modifications may alter
the folding state of proteins and their solubility, thereby influencing protein aggregation. The
main outcome of this study is that the effect of glycation on amyloid aggregation cannot be
generalized. Indeed, being a post‐translational modification, it differentially affects the
aggregation process in proteins by promoting, accelerating, and/or stabilizing on‐pathway and
off‐pathway species (Figure 2). Molecular basis of such modulation are still poorly under‐
stood. Most of the evidence indicate that glycation strongly affects the tertiary structure of the
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target protein promoting the formation of globular amyloid‐like deposits [62, 72]. Depend‐
ing on the protein involved, glycation induces chemical modifications of the positively charged
side chains (mostly lysine, arginine, and N‐terminus), thus affecting the protein charge and
favoring the exposure of its hydrophobic surface. This effect could trigger native‐like aggre‐
gation favoring the formation of small oligomers that, being stabilized by the AGE‐derived
covalent cross‐links, do not evolve into amyloid fibrils. Recent evidence indicates that
glycation promotes the formation of the amyloid oligomeric species in several model pro‐
teins (Figure 2B). However, glycation does not necessarily induce protein oligomerization.
Due to the complexity of the glycation reaction, some AGE adducts might not evolve to the
formation of protein cross‐links. In this case, glycation seems to stabilize the monomeric form
thus inhibiting the amyloid aggregation process as observed for ribosylated human insulin
(Figure 2C). Moreover, the cross‐links of AGE‐derived oligomers do not necessarily show
amyloid properties (Figure 2D). However, AGEs‐modified proteins are always able to affect
cell viability, irrespective of amyloid properties.
Figure 2. Effects of glycation in amyloid aggregation. Protein monomers are shown as blue dots, AGE‐derived cross‐
links are shown in gray, and AGE modification are shown in red. (A) Typical amyloid aggregation pathway. Possible
effects induced by glycation: (B) promote the formation of amyloid oligomeric species stabilized by covalent cross‐
links; (C) stabilize the monomeric form thus inhibiting amyloid aggregation; (D) promote the formation of cross‐linked
nonamyloidogenic oligomers.
5. Role of glycation in the amyloid‐induced cell toxicity
The effect of glycation on the aggregation process has important implications in the patho‐
logical mechanisms involved in amyloid diseases. In most proteins, glycation has been shown
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to stabilize the aggregates in the oligomeric forms. This modification has important patholog‐
ical implications as oligomeric species are known to be far more toxic than the fibrillar
aggregates [80, 81]. The oligomeric species may interact with the cell membrane, altering its
permeability and leading to cell homeostasis imbalance and neuronal cell dysfunction [82].
Recent evidence indicates that the amyloid oligomer toxicity is not strictly related to the
oligomer properties, but rather a behavior that results from a complex interplay between the
structural properties of both oligomers and cell membrane taken as a whole. Indeed, oligom‐
ers of comparable size but different structure and biophysical properties can display differ‐
ent toxicities, possibly as a consequence of the increased exposure of hydrophobic residues
that would destabilize them and favor the interaction with the plasma membrane [83]. In this
respect, glycation could affect structural and physicochemical features of amyloid oligomers
as well as their interaction to the cell membrane and subsequently modulate and/or induce the
cell toxicity. Also, the glycated oligomeric species can induce formation of reactive oxygen
species, worsening the oxidative stress in the cell and further promoting protein glycation.
Moreover, protein glycation leads to the formation of AGEs which have a pathological role in
several diseases [84–86]. AGE adducts may therefore activate, through interaction with RAGE
receptor, inflammatory response generally associated to amyloid toxicity [13]. The AGE–
RAGE binding results in the activation of NADPH‐oxidases that leads to an increased
production of ROS. A key downstream target of RAGE is the proinflammatory Nf‐κB pathway,
which in turn leads to high RAGE expression, producing a feedback loop in which continu‐
ous activation of RAGE keeps the cellular inflammatory state activated [14, 87].
Glycated proteins are also resistant to proteasomal degradation; once proteins become
glycated at their exposed lysine residues, clearance by the ubiquitin–proteasome system would
be impaired, because ubiquitination at lysine residues, a modification that targets proteins to
the proteasome for degradation, might be impeded. Thus, accumulation of proteins as
aggregates or as depositions or inclusions in tissues might be favored after glycation.
Taking into account the above considerations, protein glycation can be considered a key
dynamic contributor to these multifactorial diseases. In fact, it can both promote the forma‐
tion of pathological oligomeric species and directly trigger cell dysfunction, damage, and death
through the AGEs formation. For these reasons, AGEs are considered key therapeutic targets
in amyloidosis, and anti‐AGEs drugs are objects of intense ongoing research. Specifically, three
main strategies have been developed to counteract the AGEs’ effects: (i) to prevent the
formation of AGEs; (ii) to break cross‐links after their formation; (iii) to prevent AGEs’ negative
effects.
In vitro and in vivo experiments have shown that many compounds including aminoguani‐
dine, antioxidants such as vitamin C and vitamin E, pyridoxamine, thiamine and its synthet‐
ic derivative benfotiamine, alpha‐lipoic acid, taurine, pimagedine, aspirin, carnosine,
metformin, pioglitazone, and pentoxifylline are able to inhibit AGE formation. Some of these
compounds have already been used in clinical practice and some others are under clinical
trials. Compounds that have been shown to break existing AGE cross‐links mainly include
alagebrium (and related ALT‐462, ALT‐486, and ALT‐946) and N‐phenacylthiazolium
bromide. Studies with the aim to counteract the negative effects of the AGEs mainly involve
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the use of natural products as polyphenols, such as resveratrol and curcumin and some
flavonoids [88–90].
However, although in vitro and in vivo studies have shown the beneficial effects of various
coumpounds, the potential clinical value of these interventions remains to be established. In
fact, it seems that safety and/or efficacy in clinical studies with these compounds are still a
concern.
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